The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Learn how personalized exercise routines can transform your COPD journey, enhance resilience, and improve your quality of ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...

Asthma diagnosis and monitoring device specialist Niox Group reported a solid end to its financial year on Thursday, ...

Sharada Gudur, a Respiratory Medicine Consultant at Lancashire Teaching Hospitals and a respiratory champion for Lancashire and South Cumbria Integrated Care Board, recently joined representatives ...

as the primary criterion for establishing the COPD prevalence. Although this fixed ratio may underestimate the prevalence of obstruction in young people and overestimate it in older individuals ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

How many cases of HMPV has India reported? The answer is: more than 15. Meanwhile, China said, “...the increase of reports ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...